导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -5.98% | 3435/4773 |
| 近一周 | -2.81% | 4664/5467 |
| 近一月 | 1.51% | 208/5421 |
| 近一季 | 3.83% | 452/5238 |
| 近半年 | -1.33% | 1905/4931 |
| 近一年 | -4.53% | 3119/4400 |
| 近两年 | 31.74% | 2191/2954 |
| 近三年 | 23.78% | 1330/2253 |
| 成立以来 | 51.96% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.72% 4316/4961 |
-4.26% 3497/5312 |
- - |
- - |
| 2025 | 9.22% 2875/4813 |
-1.76% 2770/3635 |
8.13% 348/4076 |
-0.59% 3932/4524 |
3.43% 674/4813 |
| 2024 | 32.14% 86/3463 |
2.75% 715/2808 |
0.83% 538/3014 |
25.80% 293/3129 |
1.39% 1074/3463 |
| 2023 | -4.76% 693/2656 |
-0.91% 1837/2280 |
0.09% 341/2385 |
4.70% 134/2515 |
-8.28% 2273/2655 |
| 2022 | -11.49% 244/2207 |
-4.97% 173/1919 |
-1.34% 1711/2016 |
-10.14% 350/2113 |
5.06% 492/2208 |
| 2021 | -7.83% 1041/1822 |
-1.30% 462/1255 |
-2.57% 1215/1330 |
-4.68% 727/1466 |
0.56% 1092/1822 |
| 2020 | 5.45% 885/1250 |
-13.71% 937/1028 |
4.34% 909/1067 |
9.95% 601/1164 |
6.52% 754/1184 |
| 2019 | 32.31% 450/1092 |
27.08% 362/739 |
0.79% 150/788 |
-2.99% 719/850 |
6.49% 602/918 |
| 2018 | -18.81% 150/834 |
- - |
-12.32% 386/631 |
6.37% 48/660 |
-8.95% 111/682 |
| 2017 | 16.92% 231/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.12% 256/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4796 | 32.41% |
| 港股通药 | 0.9109 | 32.37% |
| 万家中证港股通创新药ETF | 1.6293 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6918 | 32.17% |
| 天弘恒生沪深港创新药精选50ETF | 0.8599 | 32.08% |
| 港股医疗 | 0.9703 | 31.90% |
| 港医疗 | 0.9212 | 31.83% |
| 港股通医疗ETF工银 | 0.9798 | 31.81% |
| 港股通医疗ETF华宝 | 0.9918 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4193 | 31.06% |
| 嘉实中证金融地产ETF联接A VS. 长安沪深300非周期A(740101) |